DARMSTADT, GERMANY: Merck has opened a meglumine manufacturing facility in Mollet des Valles, Spain. Meglumine is an amino sugar derived from glucose. It is an FDA-approved excipient for pharmaceuticals and a component of medical imaging contrast media.
The facility, validated by the FDA, is the only location in Europe that manufactures meglumine. The facility in Spain is solely dedicated to the production of meglumine, thereby ensuring continuity of supply to customers as well as meeting increasing demand for the excipient. As an excipient, meglumine interacts directly with active pharmaceutical ingredients to increase solubility. Hence, the manufacture of meglumine must meet the same stringent regulatory and quality requirements as APIs.
“Our new facility was enhanced around the manufacturing process to achieve greater efficiencies and meets the most stringent quality standards for manufacturing meglumine. The result is a high level of confidence in quality and security of supply for our customers,” said Andrew Bulpin, head of process solutions strategic marketing & innovation, Life Science.
Read More: Merck opens new meglumine production facility in Spain
No comments:
Post a Comment